Tue, February 28, 2012
[ Tue, Feb 28th 2012 ] - Market Wire
Alere to Acquire eScreen, Inc.
[ Tue, Feb 28th 2012 ] - Market Wire
ICON Acquires PriceSpective
Mon, February 27, 2012
Sat, February 25, 2012
Fri, February 24, 2012
[ Fri, Feb 24th 2012 ] - Market Wire
BrainStorm Featured on CNBC
Thu, February 23, 2012
[ Thu, Feb 23rd 2012 ] - Market Wire
00 am ET
Wed, February 22, 2012
Tue, February 21, 2012
Mon, February 20, 2012
Sat, February 18, 2012
Fri, February 17, 2012
Thu, February 16, 2012
Wed, February 15, 2012

Isis Pharmaceuticals' 2011 Financial Results and Highlights Conference Call


//health-fitness.news-articles.net/content/2012/ .. cial-results-and-highlights-conference-call.html
Published in Health and Fitness on Wednesday, February 22nd 2012 at 4:05 GMT by Market Wire   Print publication without navigation


Webcast Alert: Isis Pharmaceuticals' 2011 Financial Results and Highlights Conference Call -- CARLSBAD, Calif., Feb. 22, 2012 /PRNewswire/ --

Webcast Alert: Isis Pharmaceuticals' 2011 Financial Results and Highlights Conference Call

[ ]

CARLSBAD, Calif., Feb. 22, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: [ ISIS ]) announces the following webcast:

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

What:

Isis Pharmaceuticals' 2011 Financial Results and Highlights

When:

Wednesday, February 29, 2012 at 8:30 a.m. ET / 5:30 a.m. PT

Where:

[ www.isispharm.com ]

How:

Live on the Internet.  Simply log onto our Web site listed above.

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at [ www.isispharm.com ].

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at [ www.isispharm.com ].

SOURCE Isis Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]


Publication Contributing Sources